Regeneron says it expects to avoid new US pharma tariffs

Regeneron said it expects to be excluded from a U.S. list of pharmaceutical companies that could face new tariffs. That removes a potential tariff-related cost/headwind for the company, a modest positive for Regeneron and the sector, but is unlikely to materially move markets.

Analysis

Regeneron said it expects to be excluded from a U.S. list of pharmaceutical companies that could face new tariffs. That removes a potential tariff-related cost/headwind for the company, a modest positive for Regeneron and the sector, but is unlikely to materially move markets.